Table 1

Sample characteristics, main outcome and background variables; Average, [proportion] standard deviation
Risperidone LAI Group n = 26 Oral Medication Group n = 24 Total group n = 50
Demographic variables
Age, years 36.8 (10.81) 42.58 (10.71) 39.6 (11.04)
Gender 73% Male, 70% Male 72% Male,
Ethnicity 77% White, 54% White, 66% White,
Substance use/abuse 46% No, 58% No 52% No,
Clinical symptoms
Median (IQR) Median (IQR) Total Group
Baseline Follow-up Baseline Follow-up Baseline
PANSS total 80 (67–91) 71.5 (51–88) 71 (62.5-86) 60 (41–86) 80 (65–90)
PANSS Positive 16.5 (14–26) 15.5 (12–22) 17 (13–21) 15 (10–21) 18 (13–22)
PANSS Negative 21 (14–25) 17 (13–21) 20 (17.5-25) 16 (11–22) 21.5 (17–27)
CGI-Severity 4.5 (4–5) 3.5 (3–5) 4 (3–5) 3 (2–4) 4 (3–5)
AIMS 0 (0–1) 0 (0–0) 1 (0–3.5) 0 (0–1) 0 (0–3)
Quality of life
AQOL Illness 0.42 (0.17-0.52) 0.52 (0.42-0.64) 0.36 (0.14-0.59) 0.42 (0.26-0.53) 0.40 (0.15-0.52)
AQOL Activities Daily Life 0.78 (0.62-0.0.86) 0.88 (0.78-1.00) 1.00 (0.78-1.00) 1.00 (0.79-1.00) 0.79 (0.62-1.00)
AQOL Social 0.70 (0.27-0.82) 0.74 (0.35-0.88) 0.69 (0.24-0.88) 0.74 (0.35-0.94) 0.69 (0.24-0.83)
AQOL Physical 1.00 (0.82-1.00) 0.93 (0.82-1.00) 1.00 (0.94-1.00) 1.00 (0.94-1.00) 1.00 (0.88-1.00)
AQOL Psychological 0.87 (0.73-0.91) 0.91 (0.73-0.93) 0.87 (0.67-0.93) 0.95 (0.83-1.00) 0.87 (0.70-0.93)
Mean (sd) Mean (sd) Mean (sd) Mean (sd) Mean (sd)
Working Alliance (prorated) 48.33 (33.10) 27.30 (27.90) 45.97 (31.64) 49.30 (35.32) 48.20 (32.08)

Wykes et al.

Wykes et al. BMC Psychiatry 2013 13:28   doi:10.1186/1471-244X-13-28

Open Data